期刊
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
卷 16, 期 7, 页码 751-755出版社
TAYLOR & FRANCIS AS
DOI: 10.1080/14737159.2016.1184974
关键词
Breast cancer; circulating cell free DNA; circulating tumour DNA; liquid biopsy; genetic profiling; monitoring; next generation sequencing; digital droplet PCR
类别
资金
- Cancer Research UK [C14315/A13462X]
- Hope Against Cancer
- Cancer Research UK [13462] Funding Source: researchfish
- Pancreatic Cancer UK [2013 RIF - Shaw] Funding Source: researchfish
Introduction: Recent advances in deep amplicon sequencing have enabled rapid assessment of somatic mutations and structural changes in multiple cancer genes in DNA isolated from tumour tissues and circulating cell-free DNA (cfDNA). This cfDNA is under investigation as a 'liquid biopsy' for the real time monitoring of patients with cancer in a growing number of research studies and clinical trials. Areas covered: Here we will provide a brief overview of the potential clinical utility of cfDNA profiling for detection and monitoring of patients with breast cancer. The review was conducted in English using PubMed and search terms including 'breast cancer', 'plasma DNA', 'circulating cell free DNA' and 'circulating tumour DNA'. Expert commentary: Liquid biopsies through circulating tumor DNA (ctDNA) enable monitoring of patients with breast cancer. The challenge ahead will be to incorporate cfDNA mutation profiling into routine clinical practice to provide patients with the most appropriate and timely treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据